Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 4, 2020, Pages

  Larkins, Nicholas G ^a   Liu, Isaac D ^b   Willis, Narelle S ^c,d   Craig, Jonathan C ^d,e   Hodson, Elisabeth M ^c,d  

^a PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORINE; IMMUNOSUPPRESSIVE AGENT; LEVAMISOLE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; PREDNISONE; RITUXIMAB; ALKYLATING AGENT; AZATHIOPRINE; MYCOPHENOLIC ACID; RIBONUCLEOSIDE;

EVIDENCE BASED MEDICINE; HUMAN; HYPERTRICHOSIS; INFUSION RELATED REACTION; NEPHROTIC SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; ADOLESCENT; CHILD; INFANT; META ANALYSIS; PRESCHOOL CHILD; RECURRENT DISEASE; SECONDARY PREVENTION;

ADOLESCENT; ALKYLATING AGENTS; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEVAMISOLE; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; PREDNISOLONE; PREDNISONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RIBONUCLEOSIDES; RITUXIMAB; SECONDARY PREVENTION;

EID: 85083477758     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002290.pub5     Document Type: Review

References (200)

1. Abeyagunawardena AS, Trompeter RS. Efficacy of levamisole as a single agent in maintaining remission in steroid dependant nephrotic syndrome [abstract no: COD.OC.5]. Pediatric Nephrology 2006;21(10):1503. [CENTRAL: CN-00602129]x-wiley/crsRef/3410620
2. Abeyagunawardena AS, Trompeter RS. Intravenous pulsed vs oral cyclophosphamide therapy in steroid dependant nephrotic syndrome [abstract no: COD.PP 54]. Pediatric Nephrology 2006;21(10):1535. x-wiley/crsRef/3410622
3. Abeyagunawardena A. Intravenous pulsed cyclophosphamide versus vincristine therapy in steroid dependant nephrotic syndrome: a randomised controlled trial [abstract no: 550P]. Pediatric Nephrology 2007;22(9):1547. x-wiley/crsRef/3410624
4. Ahn YH, Kang HG, Kim SH. Efficacy and safety of rituximab in children with refractory nephrotic syndrome: a multicenter clinical trial [abstract]. Kidney Research & Clinical Practice 2014;33(2):A1. [CENTRAL: CN-01657515]x-wiley/crsRef/13321471
5. Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, et al. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine 2018;97(46):e13157. [MEDLINE: 30431588]x-wiley/crsRef/13321472
6. Anh YH, Kim SH, Han KH, Cho HY, Shin JI, Cho MH, et al. Efficacy and safety of rituximab in children with refractory nephrotic syndrome: a multicenter clinical trial [abstract no: O39]. Pediatric Nephrology 2013;28(8):1361. [EMBASE: 71126980]x-wiley/crsRef/13321473
7. Alatas H, Wirya IG, Tambunan T, Himawan S. Controlled trial of chlorambucil in frequently relapsing nephrotic syndrome in children (a preliminary report). Journal of the Medical Association of Thailand 1978;61 Suppl 1:222-8. [MEDLINE: 342654]x-wiley/crsRef/3410626
8. Al-Saran K, Mirza K. Experience with levamisole in FR/SD childhood nephrotic syndrome in a large Saudi center [abstract no:PO03]. Pediatric Nephrology 2004;19(9):C93. x-wiley/crsRef/3410629
9. Al-Saran K, Mirza K, Al-Ghanam G, Abdelkarim M. Experience with levamisole in frequently relapsing, steroid-dependent nephrotic syndrome. Pediatric Nephrology 2006;21(2):201-5. [MEDLINE: 16222548]x-wiley/crsRef/3410628
10. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. New England Journal of Medicine 1982;306(8):451-4. [MEDLINE: 7035953]x-wiley/crsRef/3410631
11. Brodehl J, Krohn HP, Ehrich JH. The treatment of minimal change nephrotic syndrome (lipoid nephrosis): cooperative studies of the Arbeitsgemeinschaft fur Padiatrische Nephrologie (APN). Klinische Padiatrie 1982;194(3):162-5. [MEDLINE: 6752557]x-wiley/crsRef/3410632
12. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Results of the nephrotic syndrome study VIII of the APN: new standard treatment versus new standard treatment plus 8 weeks cyclosporin A [abstract]. Pediatric Nephrology 1999;13:C26. [CENTRAL: CN-00636143]x-wiley/crsRef/13321475
13. Hoyer PF. Results of the nephrotic syndrome study VIII of the APN: new standard treatment versus new standard treatment plus 8 weeks cyclosporin A [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):104A. [CENTRAL: CN-00550522]x-wiley/crsRef/13321478
14. Hoyer PF, Arbeitsgemeinschaft fur Padiatrische Nephrologie. The initial treatment of idiopathic nephrotic syndrome with prednisone and cyclosporin A: preliminary results of a therapeutic trial [abstract no: P147]. Pediatric Nephrology 1995;9(6):C91. [CENTRAL: CN-00401335]x-wiley/crsRef/13321476
15. Hoyer PF, Brodehl J. Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. Journal of the American Society of Nephrology 2006;17(4):1151–7. [MEDLINE: 16540560]x-wiley/crsRef/13321477
16. Wang CS, Travers C, McCracken C, Leong T, Gbadegesin R, Quiroga A, et al. Adrenocorticotropic hormone for childhood nephrotic syndrome: the ATLANTIS randomized trial. Clinical Journal of the American Society of Nephrology: CJASN 2018;13(12):1859-65. [MEDLINE: 30442868]x-wiley/crsRef/13321480
17. Baluarte HJ, Hiner L, Gruskin AB. Chlorambucil dosage in frequently relapsing nephrotic syndrome: a controlled clinical trial. Journal of Pediatrics 1978;92(2):295-8. [MEDLINE: 621612]x-wiley/crsRef/3410634
18. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet 1991;337(8757):1555-7. [MEDLINE: 1675705]x-wiley/crsRef/3410636
19. Barratt TM, Soothill JF. A controlled trial of cyclophosphamide in steroid sensitive relapsing nephrotic syndrome of childhood [abstract]. Nephron 1971;8:95. x-wiley/crsRef/3410638
20. Barratt TM, Soothill JF. Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet 1970;296(7671):479-2. [MEDLINE: 4194935]x-wiley/crsRef/3410639
21. Barratt TM, Cameron JS, Chantler C, Ogg CS, Soothill JF. Comparative trial of 2 weeks and 8 weeks cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Archives of Disease in Childhood 1973;48(4):286-90. [MEDLINE: 4574639]x-wiley/crsRef/3410641
22. Barratt TM, Cameron JS, Chantler C, Counahan R, Ogg CS, Soothill JF. Controlled trial of azathioprine in treatment of steroid-responsive nephrotic syndrome of childhood. Archives of Disease in Childhood 1977;52(6):462-3. [MEDLINE: 879831]x-wiley/crsRef/3410643
23. Cerkauskiene R, Kaltenis P. Comparative study of prednisolone alone and prednisolone plus fusidic acid in the treatment of children with steroid-responsive nephrotic syndrome. Medicina (Kaunas, Lithuania) 2005;41 Suppl 1:26-30. [MEDLINE: 15901972]x-wiley/crsRef/3410645
24. Chiu J, McLaine PN, Drummond KN. A controlled prospective study of cyclophosphamide in relapsing, corticosteroid-responsive, minimal-lesion nephrotic syndrome in childhood. Journal of Pediatrics 1973;82(4):607-13. [MEDLINE: 4698337]x-wiley/crsRef/3410647
25. Dayal U, Dayal AK, Shastry JC, Raghupathy P. Use of levamisole in maintaining remission in steroid-sensitive nephrotic syndrome in children.[Erratum in: Nephron 1994;67(4):507]. Nephron 1994;66(4):408-12. [MEDLINE: 8015643]x-wiley/crsRef/3410649
26. Donia A, Ammar H, Moustafa F, Sobh M. Long-term efficacy of two unconventional adjunctive therapies in minimal change nephrotic children [abstract no: SP062]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:37. x-wiley/crsRef/3410651
27. Donia AF, Ammar HM, El-Agroudy A, Moustafa F, Sobh MA. Long-term results of two unconventional agents in steroid-dependent nephrotic children. Pediatric Nephrology 2005;20(10):1420-5. [MEDLINE: 16047223]x-wiley/crsRef/3410652
28. Dorresteijn E, Kist-van Holthe J, Levtchenko E, Nauta J, Hop W, van der Heijden B. Randomized controlled trial of mycophenolate mofetil (MMF) versus cyclosporine A (CsA) in children with frequently relapsing nephrotic syndrome [abstract no: 28FC]. Pediatric Nephrology 2007;22(9):1442. [CENTRAL: CN-00636133]x-wiley/crsRef/13321482
29. Dorresteijn E, Van Elburg R, Nauta J, van der Heijden B. Intestinal permeability in patients treated with mycophenolate mofetil (MMF) for nephrotic syndrome (NS) [abstract no: 355]. Pediatric Nephrology 2010;25(9):1865-6. [EMBASE: 70438457]x-wiley/crsRef/13321483
30. Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatric Nephrology 2008;23(11):2013-20. [MEDLINE: 18622632]x-wiley/crsRef/13321484
31. Edefonti A, Ghio L, Bettinelli A, Paterlini G. Unconjugated hyperbilirubinemia due to cyclosporin A (CyA) administration in children with nephrotic syndrome (NS) [abstract no: F1.12]. Pediatric Nephrology 1987;1(4):C8. [CENTRAL: CN-00465774]x-wiley/crsRef/3410658
32. Edefonti A, Ghio L, Bettinelli A, Paterlini G, Giani M, Nebbia G, et al. Unconjugated hyperbilirubinemia due to ciclosporin administration in children with nephrotic syndrome. Contributions to Nephrology 1988;67:121-4. [MEDLINE: 3208520]x-wiley/crsRef/3410657
33. Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, et al. Cyclosporine (CSA) vs cyclophosphamide (CYC) for children with frequently relapsing/steroid dependent nephrotic syndrome (FR/SDNS): long term study [abstract]. Journal of the American Society of Nephrology 1992;3(3):310. [CENTRAL: CN-00460680]x-wiley/crsRef/3410659
34. Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, et al. Cyclosporine (CSA) vs cyclophosphamide (CYC) for children with frequently relapsing/steroid dependent nephrotic syndrome: long term study [abstract]. 9th Congress of the International Pediatric Nephrology Association; 1992 Aug 30-Sep 4; Jerusalem, Israel. 1992:C70. [CENTRAL: CN-00483820]x-wiley/crsRef/3410660
35. Ponticelli C. A multicenter controlled prospective trial with cyclosporine vs cyclophosphamide in frequent relapsers and steroid dependent patients with idiopathic nephrotic syndrome. Journal of Nephrology 1989;2(2):147-51. [EMBASE: 1991014828]x-wiley/crsRef/3410663
36. Ponticelli C. Ciclosporin in the treatment of idiopathic nephrotic syndrome [abstract]. 10th Asian Colloquium in Nephrology; 1994 Dec 2-6; Karachi, Pakistan. 1994:116. [CENTRAL: CN-00461528]x-wiley/crsRef/13321485
37. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrology Dialysis Transplantation 1993;8(12):1326-32. [MEDLINE: 8159300]x-wiley/crsRef/3410661
38. Ponticelli C, Rivolta E. Ciclosporin in minimal-change glomerulopathy and in focal segmental glomerular sclerosis. American Journal of Nephrology 1990;10 Suppl 1:105-9. [MEDLINE: 2256469]x-wiley/crsRef/3410662
39. Tirelli AS, Paterlini G, Ghio L, Edefonti A, Assael BM, Bettinelli A, et al. Renal effects of cyclosporin A in children treated for idiopathic nephrotic syndrome. Acta Paediatrica 1993;82(5):463-8. [MEDLINE: 8518523]x-wiley/crsRef/13321486
40. Gellermann J, Querfeld U. Frequently relapsing steroid-sensitive nephrotic syndrome (SSNS) in children and adolescents: treatment with mycophenolate mofetil (MMF) vs. cyclosporin A (CsA) [abstract no: OS3-FRI-172]. Pediatric Nephrology 2011;26(9):1579. [EMBASE: 70530472]x-wiley/crsRef/13321488
41. Gellermann J, Schaefer F, Querfeld U. Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome. Pediatric Nephrology 2014;29(12):2411-4. [MEDLINE: 25129204]x-wiley/crsRef/13321489
42. Gellermann J, Weber L, Pape L, Tonshoff B, Hoyer P, Querfeld U, et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. Journal of the American Society of Nephrology 2013;24(10):1689-97. [MEDLINE: 23813218]x-wiley/crsRef/13321490
43. Querfeld U, Gellermann J. A randomized cross-over multicenter trial of mycophenolate mofetil versus cyslosporin A in children with frequently relapsing nephrotic syndrome [abstract no: LB-OR04]. Journal of the American Society of Nephrology 2011;22(Abstracts):1-2B. [CENTRAL: CN-01912567]x-wiley/crsRef/13321491
44. Grupe WE, Makker SP, Ingelfinger JR. Chlorambucil treatment of frequently relapsing nephrotic syndrome. New England Journal of Medicine 1976;295(14):746-9. [MEDLINE: 958261]x-wiley/crsRef/3410670
45. Gruppen M, Bouts A, Niaudet P, Schurmans T, Knops N, Ranguelov N, et al. The levamisole study in steroid sensitive idiopathic nephrotic syndrome (SSINS): inclusion completed [abstract no: P150]. Pediatric Nephrology 2012;27(9):1712-3. [EMBASE: 71386368]x-wiley/crsRef/13321493
46. Gruppen M, Davin JC, Bouts A. Levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome: Results of a multi-center, double-blind, placebo-controlled, randomized clinical trial [abstract no: FP-S25-11]. Pediatric Nephrology 2016;31(10):1753. [EMBASE: 612479674]x-wiley/crsRef/13321494
47. Gruppen MP, Bouts AH, Davin JC. The levamisole study in steroid sensitive idiopathic nephrotic syndrome (SSINS): completion is approaching [abstract no: PS2-FRI-537]. Pediatric Nephrology 2011;26(9):1682. [EMBASE: 70530801]x-wiley/crsRef/13321495
48. Gruppen MP, Bouts AH, Jansen-van der Weide MC, Merkus MP, Zurowska A, Maternik M, et al. A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. Kidney international 2018;93(2):510-8. [MEDLINE: 29054532]x-wiley/crsRef/13321496
49. Gruppen MP, Merkus MP, Davin JC. Levamisole in steroid-sensitive nephrotic syndrome (SSNS): an international multicenter double-blind randomized trial: the last news [abstract no: COD.PP40]. Pediatric Nephrology 2006;21(10):1531. [CENTRAL: CN-01912571]x-wiley/crsRef/13321497
50. Kreeftmeijer-Vegter AR, Dorlo TP, Gruppen MP, de Boer A, de Vries PJ. Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. British Journal of Clinical Pharmacology 2015;80(2):242-52. [MEDLINE: 25677380]x-wiley/crsRef/13321498
51. Iijima K. Rituximab for childhood refractory nephrotic syndrome. Pediatrics International 2011;53(5):617-21. [MEDLINE: 21771179]x-wiley/crsRef/13321505
52. Iijima K. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: an investigator initiated, multicenter, double-blind, randomized, placebo-controlled trial. Japanese Journal of Pharmacology & Therapeutics 2011;42(Suppl 2):S82-4. [EMBASE: 600779881]x-wiley/crsRef/13321506
53. Iijima K, Sako M, Nozu K. Rituximab treatment for nephrotic syndrome in children. Current Pediatric Reports 2015;3(1):71-7. [MEDLINE: 25741456]x-wiley/crsRef/13321502
54. Iijima K, Sako M, Nozu K, Mori R, Tuchida M, Kamei K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014;384(9950):1273-81. [MEDLINE: 24965823]x-wiley/crsRef/13321500
55. Iijima K, Sako M, Nozu K, Tsuchida N, Tanaka R, Ishikura K, et al. Multicenter, double-blind, placebo-controlled, randomized trial of rituximab for the treatment of childhood-onset refractory nephrotic syndrome [abstract no: O-41]. Pediatric Nephrology 2013;28(8):1362. [CENTRAL: CN-01912565]x-wiley/crsRef/13321501
56. Iijima K, Sako M, Tsuchida N, Ohashi Y. Multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset refractory nephrotic syndrome [abstract no: SA-PO1102]. Journal of the American Society of Nephrology 2014;23(Abstracts):5B. [CENTRAL: CN-01912564]x-wiley/crsRef/13321503
57. Iijima K, Tsuchida N, Sako M. Multicenter double-blind, randomized, placebo-controlled trial of IDEC-C2B8 for the treatment of childhood-onset complicated nephrotic syndrome: clinical study protocol Number: RCRNS-01 Version: 4.0. www.med.kobe-u.ac.jp/pediat/pdf/rcrn01.pdf (accessed 4 March 2020). [CENTRAL: CN-01658465]x-wiley/crsRef/13321504
58. Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, et al. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatric Nephrology 2017;32(11):2071-8. [MEDLINE: 28664242]x-wiley/crsRef/13321507
59. Iijima K, Nakamura MS, Saito M, Ohashi Y, Yoshikawa N. Cyclosporine C2 monitoring for frequent-relapsing nephrotic syndrome in children: a multicenter randomized controlled trial [abstract no: LB-PO3157]. Journal of the American Society of Nephrology 2011;22(Abstracts):6B. [CENTRAL: CN-01912566]x-wiley/crsRef/3410672
60. Iijima K, Sako M, Oba MS, Ito S, Hataya H, Tanaka R, et al. Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial. Clinical Journal of the American Society of Nephrology: CJASN 2014;9(2):271-8. [MEDLINE: 24262503]x-wiley/crsRef/3410673
61. Nakamura MS, Iijima K, Oba MS, Honda M, Nakamura H, Nagata M, et al. Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized trial [abstract no: P-SUN191]. Pediatric Nephrology 2013;28(8):1596. x-wiley/crsRef/3410674
62. Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney International 2008;73(10):1167-73. [MEDLINE: 18305467]x-wiley/crsRef/13321509
63. Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Ijima K, et al. A 2-year, prospective, randomized, multicenter trial of cyclosporine in children with frequently relapsing nephrotic syndrome [abstract no: 497P]. Pediatric Nephrology 2007;22(9):1531. [CENTRAL: CN-00653771]x-wiley/crsRef/13321510
64. Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Nakanishi K, Matsuyama T, et al. Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Pediatric Nephrology 2015;30(3):459-68. [MEDLINE: 25277597]x-wiley/crsRef/13321511
65. Abramowicz M, Barnett HL, Edelmann CM Jr, Greifer I, Kobayashi O, Arneil GC, et al. Controlled trial of azathioprine in children with nephrotic syndrome. A report for the International Study of Kidney Disease in Children. Lancet 1970;1(7654):959-61. [MEDLINE: 4191931]x-wiley/crsRef/3410687
66. Arneil GC. International trial of azathioprine in nephrotic syndrome in childhood [abstract]. Nephron 1971;8:95. [CENTRAL: CN-00602053]x-wiley/crsRef/3410688
67. Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International Study of Kidney Disease in Children. Lancet 1974;304(7878):423-7. [MEDLINE: 4137139]x-wiley/crsRef/3410690
68. McCrory WW, Shibuya M, Lu WH, Lewy JE. Therapeutic and toxic effects observed with different dosage programs of cyclophosphamide in treatment of steroid-responsive but frequently relapsing nephrotic syndrome. Journal of Pediatrics 1973;82(4):614-8. [MEDLINE: 4698338]x-wiley/crsRef/3410692
69. Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, et al. NEPHRUTIX: A randomized, double-blind, placebo vs rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome. Journal of Autoimmunity 2018;88:91-102. [MEDLINE: 29056249]x-wiley/crsRef/13321513
70. Niaudet P. Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatric Nephrology 1992;6(1):1-3. [MEDLINE: 1536727]x-wiley/crsRef/3410694
71. Prasad N, Gulati S, Sharma RK, Singh U, Ahmed M. Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatric Nephrology 2004;19(5):494-8. [MEDLINE: 15015070]x-wiley/crsRef/3410696
72. Rashid HU, Ahmed S, Fatima N, Khanam A. Levamisole in the treatment of steroid dependent or frequent relapsing nephrotic syndrome in children. Bangladesh Renal Journal 1996;15(1):6-8. [EMBASE: 1996266847]x-wiley/crsRef/3410698
73. Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clinical Journal of the American Society of Nephrology: CJASN 2011;6(6):1308-15. [MEDLINE: 21566104]x-wiley/crsRef/3410700
74. Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, et al. Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. Journal of the American Society of Nephrology 2015;26(9):2259-66. [MEDLINE: 25592855]x-wiley/crsRef/3410702
75. Omitted dates of ethical approval and timing of patient recruitment. JAMA Pediatrics 2018;172(12):1205. [MEDLINE: 30304347]x-wiley/crsRef/13321518
76. Basu A, Sander A, Preussler S, Sinha Mahapatra T, Schaefer F. Long-term efficacy of rituximab & MMF maintenance - therapy in childhood SDNS [abstract no: IPN11036-82]. Pediatric Nephrology 2019;34(10):2003. x-wiley/crsRef/13321515
77. Basu B. Randomized clinical trial to compare efficacy and safety of rituximab to that of calcineurin inhibitor in children with steroid dependent nephrotic syndrome. Protocol version 1.2 (final version). www.jamanetwork.com/journals/jamapediatrics/fullarticle/2685284?resultClick=24 (accessed 4 March 2020). x-wiley/crsRef/13321517
78. Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TK, et al. Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatrics 2018;172(8):757-64. [MEDLINE: 29913001]x-wiley/crsRef/13321516
79. Schaefer F. Superior efficacy of rituximab vs tacrolimus in pediatric steroid dependent nephrotic syndrome [abstract]. 54th ERA-EDTA Congress; 2017 June 3-6; Madrid, Spain. 2017. x-wiley/crsRef/13321519
80. Bagga A, Bhatia D, Puraswani M, Hari P, Sinha A. Randomized trial comparing efficacy & safety of mycophenolate mofetil and levamisole in frequently relapsing & steroid dependent nephrotic syndrome [abstract no: P-SUN199]. Pediatric Nephrology 2013;28(8):1599-600. [EMBASE: 71127678]x-wiley/crsRef/13321521
81. Sinha A, Peruswami M, Rawat M, Hari P, Bagga A. Randomized controlled trial to compare the efficacy and safety of mycophenolate mofetil versus levamisole in children with frequently relapsing and steroid dependent nephrotic syndrome [abstract]. Pediatric Nephrology 2015;29(12):2434. [CENTRAL: CN-01912558]x-wiley/crsRef/13321522
82. Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A. Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Kidney International 2019;95(1):2010-8. [MEDLINE: 30497684]x-wiley/crsRef/13321523
83. Sural S, Pahari DK, Mitra K, Bhattacharya S, Mondal S, Taraphder A. Efficacy of levamisole compared to cyclophosphamide and steroid in frequently relapsing (FR) minimal change nephrotic syndrome (MCNS) [abstract no: A0660]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):126A. x-wiley/crsRef/3410704
84. Uddin GM, Rahman MA, Rahman MH, Roy RR, Begum A, Huque SS. Comparative efficacy of mycophenolate mofetil and cyclosporine in children with frequent relapse nephrotic syndrome [abstract no: PO-276]. Pediatric Nephrology 2016;31(10):1852-3. [EMBASE: 612479647]x-wiley/crsRef/13321525
85. Ueda N, Kuno K, Ito S. Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. Archives of Disease in Childhood 1990;65(10):1147-59. [MEDLINE: 2248508]x-wiley/crsRef/3410706
86. Weiss R. Results of a randomized, double-blind, placebo controlled, multi-center clinical trial of levamisole for the treatment of children with frequently relapsing or steroid dependent nephrotic syndrome. Personal communication 2005. x-wiley/crsRef/3410709
87. Weiss R, NY, NJ, Phila. Pediatric Nephrology Study Group. Randomized, double-blind, placebo (P) controlled trial of levamisole (L) for children (CH) with frequently relapsing/steroid dependant (FR/SD) nephrotic syndrome (NS) [abstract no: 98P]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):289. [CENTRAL: CN-00520404]x-wiley/crsRef/3410708
88. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney International 2000;58(1):317-24. [MEDLINE: 10886577]x-wiley/crsRef/3410711
89. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. Placebo-controlled trial of mizoribine (MZR) in children with frequently relapsing nephrotic syndrome (FRNS). The Pediatric Mizoribine Study Group [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):163A. [CENTRAL: CN-00448484]x-wiley/crsRef/3410712
90. Zhang B, Liu T, Wang W, Zhang X, Fan S, Liu Z, et al. A prospective randomly controlled clinical trial on azithromycin therapy for induction treatment of children with nephrotic syndrome. European Journal of Pediatrics 2014;173(4):509-15. [MEDLINE: 24240666]x-wiley/crsRef/13321527
91. Zhang BL, Liu T. A prospective clinical randomized controlled trial on azithromycin therapy in induction treatment in children with nephrotic syndrome [abstract no: O-44]. Pediatric Nephrology 2013;28(8):1364. [EMBASE: 71126985]x-wiley/crsRef/13321528
92. Arun S, Bagga A, Bhatnagar S, Hari P, Menon S, Saini S. Efficacy of zinc (Zn) in reducing relapses in steroid sensitive nephrotic syndrome (SSNS): double blind, randomized controlled trial (RCT) (CRG030600044) [abstract no: 184]. Pediatric Nephrology 2007;22(9):1481. [CENTRAL: CN-00724915]x-wiley/crsRef/3410716
93. Arun S, Bhatnagar S, Menon S, Saini S, Hari P, Bagga A. Efficacy of zinc supplements in reducing relapses in steroid-sensitive nephrotic syndrome. Pediatric Nephrology 2009;24(8):1583-6. [MEDLINE: 19347367]x-wiley/crsRef/3410717
94. Basu B, Pandey R, Mahapatra TK, Mondal N, Schaefer F. WITHDRAWN: Efficacy and safety of mycophenolate mofetil versus levamisole in children and adolescents with idiopathic nephrotic syndrome: results of a randomized clinical trial. American Journal of Kidney Diseases 2015 Jun 09. [MEDLINE: 26071057]x-wiley/crsRef/3410719
95. Basu B, Pandey R, Mishra OP. WITHDRAWN: Randomized controlled trial to compare the efficacy & safety of mycophenolate mofetil vs levamisole in children with frequent relapsing & steroid dependent nephrotic syndrome [abstract no: O-18]. Pediatric Nephrology 2013;28(8):1353. [CENTRAL: CN-01658385]x-wiley/crsRef/3410720
96. Basu B, Pandey R, Mondal N, Schaefer F. WITHDRAWN: Efficacy and safety of mycophenolate-mofetil vs levamisole in children with idiopathic nephrotic syndrome: results of a randomized clinical trial [abstract]. Nephrology Dialysis Transplantation 2014;29(Suppl 3):iii7. [EMBASE: 71491485]x-wiley/crsRef/3410721
97. Beige J, Moosmayer I, Liefeldt L, Neumayer HH, Zidek W, Peters H. Effective and safe treatment of primary nephrotic syndrome with tacrolimus (FK 506) [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):65. [CENTRAL: CN-00444378]x-wiley/crsRef/3410723
98. Cerkauskiene R, Jankauskiene A, Kaltenis P. Effect of omega-3 fatty acids on serum homocysteine in childhood steroid-sensitive nephrotic syndrome [abstract no: P011]. Pediatric Nephrology 2004;19(9):C95. x-wiley/crsRef/3410727
99. Dharmaraj R, Hari P, Bagga A. Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome. Pediatric Nephrology 2009;24(4):775-82. [MEDLINE: 19142668]x-wiley/crsRef/13321529
100. Hari P, Bagga A. Does albumin infusion augment frusemide induced diuresis in edematous children with nephrotic syndrome? [abstract no: M-PO-0834]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:285. x-wiley/crsRef/13321530
101. Fong GZ. Observation on refractory nephrotic syndrome with integrated traditional Chinese medicine (TCM) - Western medicine (WM) [abstract]. Nephrology 1997;3(Suppl 1):S125. [CENTRAL: CN-01912560]x-wiley/crsRef/3410737
102. Hu GH, Yi ZW, Wang JH, Yao JC. Effect of Triptergium wilfordii polyglycosidium on content of Th1 and Th2 in child recurrent nephrotic syndrome. Zhongguo Zhongyao Zazhi [China Journal of Chinese Materia Medica] 2008;33(4):441-3. [MEDLINE: 18533507]x-wiley/crsRef/3410749
103. Khemani S, Moorani KN. Cyclosporine versus cyclophosphamide in childhood nephrotic syndrome. Journal of the Liaquat University of Medical & Health Sciences 2016;15(2):57-62. [EMBASE: 611436094]x-wiley/crsRef/13321532
104. Kirubakaran MG, Jacob GK, Date A, Shastry JC. A controlled trial of levamisole in frequently relapsing minimal change disease [abstract]. Kidney International 1984;26(2):240. [CENTRAL: CN-01912563]x-wiley/crsRef/3410753
105. Li X, Li Z, Cheng Z. Treatment of children with simple nephrotic syndrom using prednison once per day. Acta Academiae Medicinae Hubei 1994;15(4):386-8. [EMBASE: 1995005617]x-wiley/crsRef/3410755
106. Li X, Tian J, Lin W, He X, Jiang H, Chen J. Mycophenolate mofetil therapy in primary nephrotic syndrome with hepatitis B virus infection [abstract no: F-PO1010]. Journal of the American Society of Nephrology 2005;16:557A. [CENTRAL: CN-01912562]x-wiley/crsRef/3410757
107. Liu Y, Qu X, Chen W, Zhang Y, Liu L. Efficacy of leflunomide combined with prednisone in the treatment of refractory nephrotic syndrome. Renal Failure 2016;38(10):1616-21. [MEDLINE: 27819170]x-wiley/crsRef/13321534
108. Lou T, Wang C, Chen Z, Tang H, Liu X, Yu X. Randomized controlled trial of leflunomide in the treatment of refractory nephrotic syndrome [abstract]. Journal of the American Society of Nephrology 2004;15:353A. [CENTRAL: CN-01912561]x-wiley/crsRef/3410761
109. Naigui X, Jian X, Jing H. A clinical study on low dose cyclosporin A with diltiazem in the treatment of primary nephrotic syndrome [abstract no: P203]. Nephrology 1997;3 Suppl(1):S125. [CENTRAL: CN-00461383]x-wiley/crsRef/3410769
110. Greenbaum L, Smoyer W. Randomized trial comparing rituximab against mycophenolate mofetil in children wtih refractory nephrotic syndrome (RAMP). www.clinicaltrials.gov/ct2/show/NCT02390362 (first received 17 March 2015). x-wiley/crsRef/3410852
111. Ni ZH, Qian JQ, Lin AW, Mu S, Zhu ML, Fang W. A controlled, prospective study of efficacy of leflunomide in patients with nephrotic syndrome [abstract no: SA-PO1025]. Journal of the American Society of Nephrology 2003;14(Nov):524A. [CENTRAL: CN-00520368]x-wiley/crsRef/3410771
112. Nishiyama J, Nakabayashi I, Moriya H, Kikuchi Y, Yoshizawa N. Effect of combined treatment with methylprednisolone pulse and nafamostat mesilate for nephrotic syndrome [abstract no: P221]. Nephrology 1997;3(Suppl 1):S130. [CENTRAL: CN-01912557]x-wiley/crsRef/3410773
113. Pecoraro C, Caropreso MR, Malgieri G, Ferretti A, Nuzzi F. Therapy of first episode steroid responsive nephrotic syndrome (FESRNS): a randomised controlled trial [abstract no: MP087]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v230. x-wiley/crsRef/3410775
114. Pecoraro C, Caropreso MR, Malgieri G, Ferretti AV, Raddi G, Piscitelli A, et al. Therapy of first episode of steroid responsive nephrotic syndrome: a randomised controlled trial [abstract no: OFC41]. Pediatric Nephrology 2004;19(9):C72. [CENTRAL: CN-00644160]x-wiley/crsRef/3410776
115. Pecoraro C, Caropreso MR, Passaro G, Ferretti AV, Malgieri G. Therapy of first episode of steroid responsive nephrotic syndrome: a randomised controlled trial [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):63. [CENTRAL: CN-00447140]x-wiley/crsRef/3410777
116. Rowe PC, McLean RH, Ruley EJ, Salcedo JR, Baumgardner RA, Zaugg B, et al. Intravenous immunoglobulin in minimal change nephrotic syndrome: a crossover trial. Pediatric Nephrology 1990;4(1):32-5. [MEDLINE: 2206878]x-wiley/crsRef/3410781
117. Samuels R, Mani UV, Iyer UM, Nayak US. Hypocholesterolemic effect of spirulina in patients with hyperlipidemic nephrotic syndrome. Journal of Medicinal Food 2002;5(2):91-6. [MEDLINE: 12487756]x-wiley/crsRef/3410783
118. Sancewicz-Pach K, Slowiaczek E, Kwinta-Rybicka J, Wilkosz K, Nowak J. Results for 8-week and 12-month cyclosporin A treatment in children with primary nephrotic syndrome [abstract]. XIIIth International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:270. x-wiley/crsRef/3410785
119. Sasinka M, Plenta I, Kaiserova E, Izakovic V, Pavlovic M, CYTEMBENA/*THER USE, et al. Comparison of the effectiveness of cyclophosphamide and cytembena in controlled clinical trial in nephrotic syndrome and chronic glomerulonephritis [Porovnanie ucinnosti Cyclophosphamidu a Cytembeny v kontrolovanom klinickom pokuse pri nefrotickom syndrome a chronickej glomerulonefritide]. Ceskoslovenska Pediatrie 1976;31(3):127-30. [MEDLINE: 773556]x-wiley/crsRef/3410787
120. Shendurnikar N, Agrawal N, Nayak US, Samuels R, Mani UV. Spirulina supplementation in pediatric nephrotic syndrome [abstract]. Pediatric Nephrology 2004;19(9):C105. [CENTRAL: CN-01912556]x-wiley/crsRef/3410789
121. Stavrovskaya E, Neverov N, Shvetsov M, Tareeva I. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin 2 receptor blockers (ARB) attenuate hypercholesterolemia in patients with chronic nephrotic glomerulonephritis [abstract]. 38th Congress of the European Renal Association European Dialysis & Transplant Association; 2001 Jun 24-27; Vienna, Austria. 2001:96. [CENTRAL: CN-00461795]x-wiley/crsRef/3410791
122. Tejani A, Gonzalez R, Rajpoot D, Sharma R, Pomrantz A. A randomized trial of cyclosporine with low-dose prednisone compared with high-dose prednisone in nephrotic syndrome. Transplantation Proceedings 1988;20(3 Suppl 4):262-4. [MEDLINE: 3381280]x-wiley/crsRef/3410799
123. Tejani A, Suthanthiran M, Pomrantz A. A randomized controlled trial of low-dose prednisone and ciclosporin versus high-dose prednisone in nephrotic syndrome of children. Nephron 1991;59(1):96-9. [MEDLINE: 1944755]x-wiley/crsRef/3410800
124. Tejani A, Suthanthiran M, Rajpoot D, Gonzalez R, Pomrantz A. Randomized trial of cylosporine and low dose prednisone (P&CS) vs conventional prednisone (P) therapy in recent onset (< 1 yr) nephrotic syndrome (NS) [abstract]. Kidney International 1989;35(1):213. [CENTRAL: CN-01912553]x-wiley/crsRef/3410801
125. Trompeter RS, Thomson PD, Barratt TM, Soothill JF. Controlled trial of disodium cromoglycate in prevention of relapse of steroid-responsive nephrotic syndrome of childhood. Archives of Disease in Childhood 1978;53(5):430-2. [MEDLINE: 96741]x-wiley/crsRef/3410803
126. Urdaneta Carruyo E, Zuniga Armendariz V, Gordillo Paniagua G. Therapeutic trial with levamisole in children with idiopathic minimal change nephrotic syndrome [Ensayo terapeutico con levamisol en ninos con sindrome nefrotico idiopatico de lesiones glomerulares minimas]. Boletin Medico del Hospital Infantil de Mexico 1983;40(2):82-8. [MEDLINE: 6344884]x-wiley/crsRef/3410805
127. Wang YP, Liu AM, Dai YW, Yang C, Tang HF. The treatment of relapsing primary nephrotic syndrome in children. Journal of Zhejiang University 2005;Science. B. 6(7):682-5. [MEDLINE: 15973773]x-wiley/crsRef/3410807
128. Wu B, Mao J, Shen H, Fu H, Wang J, Liu A, et al. Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing. Nephrology 2015;20(1):18-24. [MEDLINE: 25312783]x-wiley/crsRef/3410811
129. Yamashita F, Funatsu T, Nagayama K, Arihiro H, Anan S. Evaluation of alternate-day steroid therapy for nephrotic syndrome in childhood by cross-over study. Kurume Medical Journal 1971;18(3):153-60. [MEDLINE: 4944762]x-wiley/crsRef/3410813
130. Yi ZW, Wu XC, Xu H, Zhou LJ, Wu YB, Feng SP, et al. A prospective multicenter clinical control trial on treatment of refractory nephrotic syndrome with mycophenolate mofetil in children. Zhongguo Dangdai Erke Zazhi 2008;10(5):575-8. [MEDLINE: 18947472]x-wiley/crsRef/3410815
131. Zedan MM, El-Refaey A, Zaghloul H, Abdelrahim ME, Osman A, Zedan MM, et al. Montelukast as an add-on treatment in steroid dependant nephrotic syndrome, randomised-controlled trial. Journal of Nephrology 2016;29(4):585-92. [MEDLINE: 27032639]x-wiley/crsRef/13321536
132. Zhang Y, Huang JP, Xiao HJ, Ding J, Yao Y, Yang JY. Prospective clinical randomized controlled trial of pulse methylprednisolone therapy in children with steroid sensitive nephrotic syndrome [abstract no: 797]. Pediatric Nephrology 2007;22(9):1609. [CENTRAL: CN-01912552]x-wiley/crsRef/3410817
133. Zhi-Hong H, Ying D, Li Y. Effect of the astragalus injection on urine protein in children nephrotic syndrome [abstract]. Pediatric Nephrology 2004;19(9):C97. x-wiley/crsRef/3410819
134. Zhong ZM, Yu L, Weng ZY, Hao ZH, Zhang L, Zhang YX, et al. Therapeutic effect of Ginkgo biloba leaf extract on hypercholestrolemia in children with nephrotic syndrome. Nanfang Yeie Daxue Xuebao [Journal of Southern Medical University] 2007;27(5):682-4. [MEDLINE: 17545089]x-wiley/crsRef/3410821
135. Zhu S, Wu X. A study of leflunomide in treatment of juvenile refractory nephropathy syndrome [abstract]. Pediatric Nephrology 2013;28(8):1419. [EMBASE: 71127146]x-wiley/crsRef/3410823
136. Zou HQ, Wang YQ. Mechanism that Chinese traditional medicine reduces relapses of idiopathic nephrotic syndrome (INS) in children [abstract]. Nephrology 1997;3(Suppl 1):S124. [CENTRAL: CN-01912341]x-wiley/crsRef/3410825
137. Baudouin V. Cyclophosphamide versus mycophenolate mofetil for children with steroid-dependent idiopathic nephrotic syndrome: a multicenter randomized controlled trial. www.clinicaltrials.gov/ct2/show/NCT01092962 (first received 25 March 2010). x-wiley/crsRef/3410836
138. Kang HG. A prospective, randomized, open-label study evaluating the efficacy of mycophenolate mofetil in the prevention of relapse of steroid dependent nephrotic syndrome in children. www.clinicaltrials.gov/ct2/show/NCT01895894 (first received 11 July 2013). x-wiley/crsRef/3410850
139. Sawires H, Abdelaziz H, Ahmed HM, Botrous O, Agban M. Randomized controlled trial on immunomodulatory effects of azithromycin in children with steroid-dependent nephrotic syndrome. Pediatric Nephrology 2019;34(9):1591-7. [MEDLINE: 31089818]x-wiley/crsRef/13321538
140. Sawires H, Abdelaziz H, Mostafa O, Botrous O, Agban M. Randomized controlled trial on immunomodulatory effects of azithromycin in children with steroid dependent nephrotic syndrome [abstract no: IPN10189-90]. Pediatric Nephrology 2019;34(10):1933. x-wiley/crsRef/13321539
141. Tohjoh S, Narita M, Koyama T, Miyahara M, Nagasawa T, Kitagawa T, et al. Clinical evaluation of cyclosporin in the treatment of nephrotic syndrome: multicentre double-blind study. Jin Tohseki 1994;37:565-608. x-wiley/crsRef/3410840
142. Hama T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Sako M, et al. Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial). BMC Nephrology 2018;19(1):223. [MEDLINE: 30200895]x-wiley/crsRef/13321541
143. Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, et al. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07). BMC Nephrology 2018;19(1):302. [MEDLINE: 30382824]x-wiley/crsRef/13321543
144. Benz MR, Doetsch J, Ehren R, Gellermann J, Haffner D, Hoyer PF, et al. Protocol of an open, randomized, controlled, multicenter trial on the initial treatment of idiopathic steroid-sensitive nephrotic syndrome in children with mycophenolate mofetil vs. prednisone: the Intent Study [abstract no: P176]. Pediatric Nephrology 2014;29(9):1740. [EMBASE: 71662573]x-wiley/crsRef/13321545
145. Ehren R, Benz MR, Doetsch J, Fichtner A, Gellermann J, Haffner D, et al. Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil versus prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study). BMJ Open 2018;8(10):e024882. [MEDLINE: 30309995]x-wiley/crsRef/13321546
146. Tonshoff B. Initial treatment of idiopathic nephrotic syndrome in children with mycophenolate mofetil vs. prednisone: a randomized, controlled, multicenter study (INTENT Study): Clinical study protocol: Version 4.0/20150325. www.intent-study.de/.cm4all/iproc.php/Studienprotokoll_INTENT_V4_2015_03_25_signiert.pdf?cdp=a (accessed 4 March 2020). x-wiley/crsRef/13321547
147. Nagano C, Sako M, Kamei K, Ishikura K, Nakamura H, Nakanishi K, et al. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial). BMC Nephrology 2019;20(1):293. [MEDLINE: 31375087]x-wiley/crsRef/13321549
148. Veltkamp F, Khan DH, Reefman C, Veissi S, van Oers HA, Levtchenko E, et al. Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: study protocol for a double blind, randomised placebo-controlled trial (the LEARNS study). BMJ Open 2019;9(8):e027011. [MEDLINE: 31375606]x-wiley/crsRef/13321551
149. Veltkamp F, Reefman C, Khan DH, Veissi S, Haverman L, Mathot RA, et al. Prevention of relapses with levamisole as adjuvant therapy to corticosteroids in children with a first episode of idiopathic nephrotic syndrome – an international, double blind, placebo-controlled randomized trial [abstract no: O-327]. Pediatric Nephrology 2018;33(10):1938. x-wiley/crsRef/13321552
150. Dossier C. Efficiency of levamisole for maintaining remission after the first flare of steroid sensitive nephrotic syndrome in children (NEPHROVIR3). www.clinicaltrials.gov/show/NCT02818738 (first received 30 June 2016). x-wiley/crsRef/13321554
151. Li Y. Availability study of ACTH to treat children SRNS/SDNS. www.clinicaltrials.gov/show/NCT02972346 (first received 23 November 2016). x-wiley/crsRef/13321556
152. Ravani P, Bonanni A, Ghiggeri GM. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. BMJ Open 2017;7(3):e013319. [MEDLINE: 28314744]x-wiley/crsRef/13321558
153. Basu B. Compare efficacy and safety of repeated courses of rituximab to that of maintenance mycophenolate mofetil following single course of rituximab among children with steroid dependent nephrotic syndrome (RITURNS II). www.clinicaltrials gov/ct2/show/NCT03899103 (first received 2 April 2019). x-wiley/crsRef/13321560
154. Hogan J, Deschenes G. Efficacy and safety of immunoglobulin associated with rituximab versus rituximab alone in childhood-onset steroid-dependent nephrotic syndrome (RITUXIVIG). www.clinicaltrials.gov/ct2/show/NCT03560011 (first received 18 June 2018). x-wiley/crsRef/13321562
155. Sinha A, Raut S, Ghanapriya K, Bhardwaj M, Kalra S, Hari P, et al. Alternate-day prednisolone made daily during infections versus levamisole for frequently-relapsing nephrotic syndrome [abstract no: IPN12086-88]. Pediatric Nephrology 2019;34(10):2171-2. x-wiley/crsRef/13321564
156. Arneil GC. 164 children with nephrosis. Lancet 1961;2(7212):1103-10. [MEDLINE: 13862397]
157. Choudhry S, Bagga A, Panka H, Sharma S Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. American Journal of Kidney Diseases 2009;53(5):760-9. [MEDLINE: 19268410]
158. Coutinho HM, Groothoff JW, Offringa M, Gruppen MP, Heymans HS. De novo malignancy after paediatric renal replacement therapy. Archives of Disease in Childhood 2001;85(6):478-83. [MEDLINE: 11719332]
159. Crowther CA, Crosby DD. Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD000164.pub2]
160. El Bakkali L, Rodrigues Pereira R, Kuik DJ, Ket JC, van Wijk JA. Nephrotic syndrome in The Netherlands: a population-based cohort study and a review of the literature. Pediatric Nephrology 2011;26(8):1241-6. [MEDLINE: 21533870]
161. Fairley KF, Barrie JU, Johnson W. Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet 1972;1(7750):568-9. [MEDLINE: 4110052]
162. Haute Autorité de Santé. Idiopathic nephrotic syndrome in children. National protocol for diagnosis and treatment for a rare disease [Syndrome néphrotique idiopathique de l’enfant. Protocole national de diagnostic et de soins pour une maladie rare]. http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-06/pnds_sni_enfant.pdf (accessed prior to 4 March 2020).
163. Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009;124(2):747-57. [MEDLINE: 19651590]
164. Glenton C, Santesso N, Rosenbaum S, Nilsen E, Rader T, Ciapponi A, et al. Presenting the results of Cochrane Systematic Reviews to a consumer audience: a qualitative study. Medical Decision Making 2010;30(5):566-77. [MEDLINE: 20643912]
165. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: 18436948]
166. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [MEDLINE: 21195583]
167. Hahn D, Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD001533.pub5]
168. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
169. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
170. Hogg R, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, et al. Multicenter trial of mycophenolate mofetil (MMF) in children with steroid dependent (SD) or frequent relapsing (FR) nephrotic syndrome (NS). Report of the Southwest Pediatric Nephrology Study Group [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):261.
171. Indian Pediatric Nephrology Group-Indian Academy of Pediatrics, Bagga A, Ali U, Banerjee S, Kanitkar M, Phadke KD, et al. Management of steroid-sensitive nephrotic syndrome: revised guidelines. Indian Pediatrics 2008;45(3):203-14. [MEDLINE: 18367765]
172. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney International 1978;13(2):159-65. [MEDLINE: 713276]
173. Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the International Study of Kidney Disease in Children. Journal of Pediatrics 1982;95(2):239-43. [MEDLINE: 109598]
174. Nishi S, Ubara Y, Utsunomiya Y, Okada K, Obata Y, Kai H, et al. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clinical & Experimental Nephrology 2014;20(3):342-70. [MEDLINE: 27099136]
175. KDIGO Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney International Supplements 2012;2(2):139-274. [www.kdigo.org/wp-content/uploads/2017/02/KDIGO-2012-GN-Guideline-English.pdf]
176. Kemper M, Wolf G, Müller-Wiefel D. Transmission of glomerular permeability factor from a mother to her child. New England Journal of Medicine 2001;344(5):386-7. [MEDLINE: 11195803]
177. Koskimies O, Vilska J, Rapola J, Hallman N. Long-term outcome of primary nephrotic syndrome. Archives of Disease in Childhood 1982;57(7):544-8. [MEDLINE: 7103547]
178. McKinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatric Nephrology 2001;16(12):1040-4. [MEDLINE: 11793096]
179. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13. [MEDLINE: 9746022]
180. Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet 2018;392(10143):61-74. [MEDLINE: 29910038]
181. Querfeld U, Weber LT. Mycophenolate mofetil for sustained remission in nephrotic syndrome. Pediatric Nephrology 2018;33(12):2253-65. [MEDLINE: 29750317]
182. Queshi MS, Pennington JH, Goldsmith HJ, Cox PE. Cyclophosphamide therapy and sterility. Lancet 972;2(7790):1290-1. [MEDLINE: 4117814]
183. Rapola J, Koskimies O, Huttunen NP, Floman P, Vilska J, Hallman N. Cyclophosphamide and the pubertal testis. Lancet 1973;1(7794):98-9. [MEDLINE: 4118670]
184. Savin VJ, Sharma J, Sharma M, McCarthy ET, Swan SK, Ellis E, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. New England Journal of Medicine 1996;354(14):878-83. [MEDLINE: 8596570]
185. Schlesinger ER, Sultz HA, Mosher WE, Feldman JG. The nephrotic syndrome: its incidence and implications for the community. American Journal of Diseases of Children 1968;116(6):623-32. [MEDLINE: 5697193]
186. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [MEDLINE: 7823387]
187. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
188. Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
189. Pasini A, Benetti E, Conti G, Ghio L, Lepore M, Massella L, et al. The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse. Italian Journal of Pediatrics 2017;43(1):41. [MEDLINE: 28427453]
190. Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrology Dialysis Transplantation 2006;21(7):1848-54. [MEDLINE: 16311257]
191. Sureshkumar P, Hodson EM, Willis NS, Barzi F, Craig JC. Predictors of remission and relapse in idiopathic nephrotic syndrome: a prospective cohort study. Pediatric Nephrology 2014;29(6):1039-46. [MEDLINE: 24488504]
192. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. Journal of the American Society of Nephrology 1997;8(5):769-76. [MEDLINE: 9176846]
193. Wang W, Xia Y, Mao J, Chen Y, Wang D, Shen H, et al. Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatric Nephrology 2012;27(11):2073-9. [MEDLINE: 22714672]
194. Wong W. Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study. Journal of Paediatrics & Child Health 2007;43(5):337-41. [MEDLINE: 17489822]
195. Durkan A, Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD002290]
196. Durkan A, Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002290]
197. Durkan AM, Hodson EM, Willis NS, Craig JC. Immunosuppressive agents in childhood nephrotic syndrome: a meta-analysis of randomized controlled trials. Kidney International 2001;59(5):1919-27. [MEDLINE: 11318964]
198. Durkan A, Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002290.pub2]
199. Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD002290.pub3]
200. Pravitsitthikul N, Willis NS, Hodson EM, Craig JC. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD002290.pub4]